quinoxalines has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD | 1 |
| Alousi, AM; Boinpally, R; DeLuca, P; Gadgeel, S; Heilbrun, LK; LoRusso, PM; Parchment, R; Wiegand, R; Wozniak, AJ | 1 |
2 trial(s) available for quinoxalines and Neutropenia
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Quinoxalines; Treatment Outcome | 2008 |
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Protein Binding; Quinoxalines; Topoisomerase II Inhibitors; Treatment Outcome | 2007 |